Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Cann Group ( (AU:CAN) ) is now available.
Cann Group Limited announced the results of its General Meeting, where all resolutions were passed following a poll vote. The meeting included significant decisions such as the election of a director and the ratification of share and option issuances, which are expected to impact the company’s strategic direction and stakeholder interests positively.
More about Cann Group
Cann Group Limited is an Australian company focused on enhancing patients’ lives through the development, production, and supply of innovative cannabis medicines. The company operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, supplying a range of dried flower, oil products, active pharmaceutical ingredients, and extracts to both Australian and international markets. Cann Group also owns Satipharm, known for its patent-protected capsule technology.
Average Trading Volume: 1,822,776
Technical Sentiment Signal: Sell
Current Market Cap: A$9.02M
For detailed information about CAN stock, go to TipRanks’ Stock Analysis page.